News
21h
Pharmaceutical Technology on MSNACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59The recommendation builds on the committee’s June 2024 vote for the use of RSV vaccines for people aged 60 to 74 at high risk ...
Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...
Considering taking supplements to treat respiratory tract infections? Below is a list of common natural remedies used to treat or reduce the symptoms of respiratory tract infections. Follow the ...
Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO, the company’s bivalent respiratory syncytial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results